Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

AbbVie

Status: Completed

Conditions: Hepatitis C Virus (HCV)

Study type: Observational

Funder types: Industry

Identifiers

NCT03341871

P16-570

Details and patient eligibility

About

This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.

Enrollment: 1,095 patients

Sex: All

Ages: Under 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic hepatitis C virus infection and administering glecaprevir plus pibrentasvir.

Exclusion criteria

• Patients previously treated with glecaprevir plus pibrentasvir.

Trial design

1,095 participants in 1 patient group

HCV Genotypes 1, 2, 3, 4, 5, or 6 participants

Description:

Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to the current local label.